1.	Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: D2610C00003, 2010-021220-10, NCT01202591
2.	A Trial of AZD4547 for Breast Cancer That is Oestrogen Receptor Positive and Has Got Worse Despite Having Anastrozole or Letrozole Phase: Phase II, Phase I Type: Treatment Status: Active Age: 25 and over Sponsor: Other Protocol IDs: C/23/2011, 2011-000454-32, NCT01791985
3.	Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 25 and over Sponsor: NCI, Other Protocol IDs: E2512, NCI-2012-01940, U10CA021115, NCT01824901
4.	Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 25 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D2610C00004, NCT01457846
5.	Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 25 and over Sponsor: Other Protocol IDs: 3689, NCT01795768
6.	Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours Phase: Phase I Type: Treatment Status: Active Age: 25 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D2610C00001, NCT00979134